000166277 001__ 166277
000166277 005__ 20240229123224.0
000166277 0247_ $$2doi$$a10.3390/cancers12113465
000166277 0247_ $$2pmid$$apmid:33233777
000166277 0247_ $$2pmc$$apmc:PMC7699843
000166277 0247_ $$2altmetric$$aaltmetric:94808420
000166277 037__ $$aDKFZ-2020-02770
000166277 041__ $$aeng
000166277 082__ $$a610
000166277 1001_ $$aColmenero-Repiso, Ana$$b0
000166277 245__ $$aIdentification of VRK1 as a New Neuroblastoma Tumor Progression Marker Regulating Cell Proliferation.
000166277 260__ $$aBasel$$bMDPI$$c2020
000166277 3367_ $$2DRIVER$$aarticle
000166277 3367_ $$2DataCite$$aOutput Types/Journal article
000166277 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1609263237_1255
000166277 3367_ $$2BibTeX$$aARTICLE
000166277 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000166277 3367_ $$00$$2EndNote$$aJournal Article
000166277 520__ $$aNeuroblastoma (NB) is one of the most common pediatric cancers and presents a poor survival rate in affected children. Current pretreatment risk assessment relies on a few known molecular parameters, like the amplification of the oncogene MYCN. However, a better molecular knowledge about the aggressive progression of the disease is needed to provide new therapeutical targets and prognostic markers and to improve patients' outcomes. The human protein kinase VRK1 phosphorylates various signaling molecules and transcription factors to regulate cell cycle progression and other processes in physiological and pathological situations. Using neuroblastoma tumor expression data, tissue microarrays from fresh human samples and patient-derived xenografts (PDXs), we have determined that VRK1 kinase expression stratifies patients according to tumor aggressiveness and survival, allowing the identification of patients with worse outcome among intermediate risk. VRK1 associates with cell cycle signaling pathways in NB and its downregulation abrogates cell proliferation in vitro and in vivo. Through the analysis of ChIP-seq and methylation data from NB tumors, we show that VRK1 is a MYCN gene target, however VRK1 correlates with NB aggressiveness independently of MYCN gene amplification, synergizing with the oncogene to drive NB progression. Our study also suggests that VRK1 inhibition may constitute a novel cell-cycle-targeted strategy for anticancer therapy in neuroblastoma.
000166277 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000166277 588__ $$aDataset connected to CrossRef, PubMed,
000166277 650_7 $$2Other$$aMYCN
000166277 650_7 $$2Other$$aVRK1
000166277 650_7 $$2Other$$ahigh-risk
000166277 650_7 $$2Other$$aneuroblastoma
000166277 650_7 $$2Other$$aproliferation
000166277 650_7 $$2Other$$atumorigenesis
000166277 7001_ $$00000-0002-6478-8197$$aGómez-Muñoz, María A$$b1
000166277 7001_ $$aRodríguez-Prieto, Ismael$$b2
000166277 7001_ $$00000-0001-5692-1202$$aAmador-Álvarez, Aida$$b3
000166277 7001_ $$0P:(DE-He78)a579ca2567736066534409e732b31c91$$aHenrich, Kai-Oliver$$b4$$udkfz
000166277 7001_ $$aPascual-Vaca, Diego$$b5
000166277 7001_ $$0P:(DE-He78)34b3639de467b2c700920d7cbc3d2110$$aOkonechnikov, Konstantin$$b6$$udkfz
000166277 7001_ $$aRivas, Eloy$$b7
000166277 7001_ $$0P:(DE-He78)91f32735ee876c579d63c05a7f4778dd$$aWestermann, Frank$$b8$$udkfz
000166277 7001_ $$00000-0003-1085-0714$$aPardal, Ricardo$$b9
000166277 7001_ $$00000-0002-9015-864X$$aVega, Francisco M$$b10
000166277 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers12113465$$gVol. 12, no. 11, p. 3465 -$$n11$$p3465 $$tCancers$$v12$$x2072-6694$$y2020
000166277 909CO $$ooai:inrepo02.dkfz.de:166277$$pVDB
000166277 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a579ca2567736066534409e732b31c91$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000166277 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)34b3639de467b2c700920d7cbc3d2110$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000166277 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)91f32735ee876c579d63c05a7f4778dd$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000166277 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000166277 9141_ $$y2020
000166277 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2018$$d2020-09-11
000166277 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-11
000166277 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-11
000166277 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-11
000166277 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-09-11
000166277 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-09-11
000166277 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-09-11
000166277 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-09-11
000166277 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-09-11
000166277 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-09-11
000166277 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-11
000166277 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-11
000166277 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-09-11
000166277 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-09-11
000166277 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-11
000166277 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-11
000166277 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2018$$d2020-09-11
000166277 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-11
000166277 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-11
000166277 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000166277 9201_ $$0I:(DE-He78)B087-20160331$$kB087$$lB087 Neuroblastom Genomik$$x1
000166277 980__ $$ajournal
000166277 980__ $$aVDB
000166277 980__ $$aI:(DE-He78)B062-20160331
000166277 980__ $$aI:(DE-He78)B087-20160331
000166277 980__ $$aUNRESTRICTED